Asset
GLEMBATUMUMAB VEDOTIN
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01156753 | phase2 | completed | 2010-07-01 | 2012-10-01 | Celldex Therapeutics | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer |
| NCT02302339 | phase2 | terminated | 2014-11-01 | 2018-06-14 | Celldex Therapeutics | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma |
| NCT01997333 | phase2 | completed | 2013-11-01 | 2017-11-30 | Celldex Therapeutics | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.